Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRSS1 | P07477 | 8/20 | 0.45 |
| ▸ | TMPRSS15 | P98073 | 8/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | ITGB3 | P05106 | 2/20 | 0.41 |
| ▸ | ITGA2B | P08514 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.40 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16356102 | 1.00 | PRSS1 (0.45) | PRSS1TMPRSS15GAAALDH1A1ITGB3 | |
| SCHEMBL16356097 | 0.93 | PRSS1 (0.50) | PRSS1TMPRSS15ALDH1A1ITGB3ITGA2B | |
| SCHEMBL16356117 | 0.92 | KMT2A (0.48) | PRSS1TMPRSS15ALDH1A1ITGB3ITGA2B | |
| SCHEMBL16356116 | 0.91 | TMPRSS15 (0.48) | PRSS1TMPRSS15GAAHTTMEN1 | |
| SCHEMBL16356125 | 0.91 | TMPRSS15 (0.48) | PRSS1TMPRSS15GAAHTTMEN1 | |
| SCHEMBL16356089 | 0.90 | PRSS1 (0.46) | PRSS1TMPRSS15ALDH1A1ITGB3ITGA2B | |
| SCHEMBL16356107 | 0.90 | PRSS1 (0.46) | PRSS1TMPRSS15ALDH1A1ITGB3ITGA2B | |
| SCHEMBL11309501 | 0.89 | ALDH1A1 (0.54) | PRSS1TMPRSS15GAAALDH1A1ITGB3 | |
| SCHEMBL16356101 | 0.87 | TMPRSS15 (0.50) | PRSS1TMPRSS15PRSS2PRSS3 | |
| SCHEMBL16356104 | 0.87 | TMPRSS15 (0.50) | PRSS1TMPRSS15PRSS2PRSS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9199927-B2 | Guanidinobenzoic acid compound | ASTELLAS PHARMA INC. (JP) | 2015-12-01 | — | — | US | disclosed |
| US-20140378459-A1 | GUANIDINOBENZOIC ACID COMPOUND | ASTELLAS PHARMA INC. (JP) | 2014-12-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378459-A1 | GUANIDINOBENZOIC ACID COMPOUND | SERPINB1, REN, SPINT2 | PRSS1 13/4885TMPRSS15 4/4885GAA 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.